Acoramidis improves outcomes in patients with transthyretin amyloid cardiomyopathy (ATTR-CM)
2:42
Acoramidis improves outcomes in patients with transthyretin amyloid cardiomyopathy (ATTR-CM)
2.1K viewsAug 27, 2023
YouTubeCardioInfo
🎙️ HFSA 2025 Interview | Dramatic Cardiovascular Outcomes with Acoramidis in ATTR-CM Dr Ahmad Masri from Oregon Health & Science University shares compelling new analysis from the ATTRibute-CM trial that provides important insights into how and when TTR stabilization therapy benefits patients with transthyretin amyloid cardiomyopathy. 🔬 The Analysis: This post hoc exploratory study examined 611 patients over 30 months, comparing acoramidis 800 mg twice daily to placebo. The patient group had r
1:31
🎙️ HFSA 2025 Interview | Dramatic Cardiovascular Outcomes with Acoramidis in ATTR-CM Dr Ahmad Masri from Oregon Health & Science University shares compelling new analysis from the ATTRibute-CM trial that provides important insights into how and when TTR stabilization therapy benefits patients with transthyretin amyloid cardiomyopathy. 🔬 The Analysis: This post hoc exploratory study examined 611 patients over 30 months, comparing acoramidis 800 mg twice daily to placebo. The patient group had r
212 views7 months ago
FacebookRadcliffe Cardiology
Acoramidis Treatment is Effective in Patients With ATTR-CM
2:43
Acoramidis Treatment is Effective in Patients With ATTR-CM
760 viewsJun 13, 2024
YouTubeDocWire
HFSA 25: The ATTRibute-CM Trial
4:12
HFSA 25: The ATTRibute-CM Trial
82 views7 months ago
YouTubeRadcliffe Cardiology
Medical University of South Carolina (MUSC) researchers played a critical role in testing Acoramidis (Attruby), a groundbreaking treatment for ATTR-CM, a condition that impacts heart health. Watch Dr. Daniel Judge share how this drug improves quality of life and could even prevent the disease in some cases. Learn more: https://web.musc.edu/about/news-center/2024/12/03/musc-plays-key-role-testing-new-treatment-for-attr-cm-serious-condition-affecting-heart #HeartHealth #MUSCResearch #ChangingWhats
0:40
Medical University of South Carolina (MUSC) researchers played a critical role in testing Acoramidis (Attruby), a groundbreaking treatment for ATTR-CM, a condition that impacts heart health. Watch Dr. Daniel Judge share how this drug improves quality of life and could even prevent the disease in some cases. Learn more: https://web.musc.edu/about/news-center/2024/12/03/musc-plays-key-role-testing-new-treatment-for-attr-cm-serious-condition-affecting-heart #HeartHealth #MUSCResearch #ChangingWhats
602 viewsDec 5, 2024
FacebookMUSC Health
Variant ATTR-CM Responds Powerfully to Acoramidis Therapy
4:40
Variant ATTR-CM Responds Powerfully to Acoramidis Therapy
37 views5 months ago
YouTubeDocWire
Acoramidis Therapy Yields Positive Results in Patients With ATTR-CM by Reducing Hospitalizations
4:38
Acoramidis Therapy Yields Positive Results in Patients With ATTR-CM by Reducing Hospitalizations
194 viewsFeb 5, 2025
YouTubeDocWire
0:50
The impact of acoramidis on clinical outcomes in ATTR-CM
726 viewsJul 9, 2024
YouTubeVJHemOnc – Video Journal of Hematology & H…
3:30
Acoramidis Reduces AF Burden in ATTR-CM: ESC 2025 Insights
153 views11 months ago
YouTubeDocWire
BridgeBio Pharma, Inc.: Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM
Mar 31, 2025
finanznachrichten.de
Acoramidis: A Potential Breakthrough Treatment for Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) | Cardiology
Jul 18, 2023
labroots.com
Unpacking ATTRibute-CM and the Role of Acoramidis for ATTR-CM
11 months ago
vumedi.com
32:02
Acoramidis: The Drug Revolutionizing ATTR-CM Treatment – A Journey from Lab to Life Changer
85 views11 months ago
YouTubeAlsan's Pharmaceutical Journey
17:13
Behind the Science: Analysis of Acoramidis on Cumulative CV Outcomes | JACC
170 views3 months ago
YouTubeAmerican College of Cardiology
BridgeBio Pharma Reports Phase 3 Data Linking TTR Increase to Improved Survival With Acoramidis
1 year ago
marketscreener.com
4:51
ATTRUBY - FDA NDA approval - 2024-11-22
222 viewsDec 11, 2024
YouTubeInside Drug Discovery
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
Nov 22, 2024
marketscreener.com
BridgeBio Pharma, Inc.: BEYONTTRA (acoramidis), the First Near Complete TTR Stabilizer (=90%), Approved by the European Commission to Treat ATTR-CM
6 months ago
finanznachrichten.de
2:02
Acoramidis, a new therapeutic alternative in ATTR-CM
443 views5 months ago
YouTubeSociedad Española de Cardiología
4:40
ESC 23: ATTRibute-CM Trial
1.5K viewsAug 28, 2023
YouTubeRadcliffe Cardiology
VIDEO: Concomitant tafamidis, acoramidis use does not alter any ATTRibute-CM endpoints
Apr 17, 2025
healio.com
ATTR-CM Hospitalization Consequences | Attruby® (acoramidis)
8 months ago
linkedin.com
2:14
【赴宜康】阿考米迪(Attruby)说明书：适应症、用法用量及效果
2 views3 months ago
bilibili赴宜康医药查询
2:09
Learn more about how Attruby can help adults with ATTR-cardiac amyloidosis. Please see Important Safety Information at Attruby.com/#ISI for Attruby® (acoramidis) and Full Prescribing Information and Patient Information at Attruby.com/PI. | Morgan Freeman
23.4K views7 months ago
FacebookMorgan Freeman
2:53
Acoramidis per il trattamento dell'ATTR-CM. Nuovi dati da ESC Congress 2025
179 views8 months ago
YouTubeCardioInfo
1:52
【海得康】Acoramidis(Attruby)适应症
5 views4 months ago
bilibili海得康咨询
FDA approves Stanford Medicine-developed drug that treats rare heart disease
Nov 27, 2024
stanford.edu
4:08
ATTRibute-CM : efficacité de l’acoramidis sur l'amylose cardiaque à transthyrétine - ESC 2023
1.4K viewsAug 30, 2023
YouTubeCardio-online
4:53
Acoramidis Cuts AFib Hospitalizations in ATTR Amyloidosis
87 views11 months ago
YouTubeDocWire
Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy
387 viewsApr 10, 2025
vumedi.com
See more